TY - JOUR T1 - Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial JF - medRxiv DO - 10.1101/2021.08.19.21262323 SP - 2021.08.19.21262323 AU - Gilmar Reis AU - Eduardo Augusto dos Santos Moreira Silva AU - Daniela Carla Medeiros Silva AU - Lehana Thabane AU - Aline Cruz Milagres AU - Thiago Santiago Ferreira AU - Castilho Vitor Quirino dos Santos AU - Adhemar Dias de Figueiredo Neto AU - Eduardo Diniz Callegari AU - Leonardo Cançado Monteiro Savassi AU - Vitoria Helena de Souza Campos AU - Maria Izabel Campos Simplicio AU - Luciene Barra Ribeiro AU - Rosemary Oliveira AU - Ofir Harari AU - Jamie I Forrest AU - Hinda Ruton AU - Sheila Sprague AU - Paula McKay AU - Alla V Glushchenko AU - Craig R. Rayner AU - Eric J. Lenze AU - Angela M. Reiersen AU - Gordon H. Guyatt AU - Edward J. Mills AU - the TOGETHER Investigators Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/23/2021.08.19.21262323.abstract N2 - Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-19, we assessed the efficacy of fluvoxamine vs. placebo in preventing either extended emergency room observation or hospitalization due to COVID-19. Herein, we report the preliminary findings.Methods This placebo-controlled, randomized, adaptive, platform trial conducted among symptomatic Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients with a known risk factor for progression to severe disease. Patients were randomly assigned to either fluvoxamine (100 mg twice daily for 10 days) or placebo. The primary endpoint was a composite outcome of emergency room observation for >6 hours or hospitalization from COVID-19 up to 28 days post randomization. Secondary outcomes included viral clearance at day 7, time to hospitalization, mortality, and adverse drug reactions. We used a Bayesian analytic framework to determine effects along with probability of success of intervention compared to placebo. The trial is registered at clinicaltrials.gov (NCT04727424) and is ongoing.Results The study team screened 9020 potential participants for this trial. The trial was initiated on June 2, 2020, with the current protocol reporting randomization from January 15, 2021 to August 6th 2021, when the trial arms were stopped for superiority. A total of 3238 patients were allocated to fluvoxamine (n=739), placebo (n=733) and other treatments (n=1766). Herein, we report the effectiveness of fluvoxamine vs. a concurrent placebo control. The average age of participants was 50 years (range 18-102 years); 57% were female. The proportion of patients observed in an emergency room for >6 hours or admitted to hospital due to COVID-19 was lower for the fluvoxamine group compared to placebo (77/739 vs 108/733; Relative Risk [RR]: 0.71; 95% Bayesian Credible Interval [95% BCI]: 0.54 - 0.93), with a probability of superiority of 99.4% surpassing the prespecified superiority threshold of 97.6% (risk difference 4.3%). Of the composite primary outcome events, 88% were hospitalizations. We found no significant relative effects between the fluvoxamine and placebo groups on viral clearance at day 7 (Odds ratio [OR]: 0.75; 95% Confidence Intervals [95% CI]: 0.53 - 1.07), mortality (OR: 0.70; 95% CI: 0.36 - 1.30), time to death (Hazard ratio [HR]: 0.79; 95% CI: 0.58 - 1.08), days hospitalized (Mean Difference (MD) 1.22 days; 95% CI: 0.98 - 1.53), number of days ventilated (MD 1.10; 95% CI: 0.70 - 1.73) or other secondary outcomes. Data capturing all 28 days of follow-up will be reported after August 26th, 2021.Conclusions Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19, reduced the need for extended emergency room observation or hospitalization.Funding The trial was supported by FastGrants and The Rainwater Foundation.Competing Interest StatementDr. Reiersen and Dr. Lenze are listed on a patent application related to methods of treating COVID-19, that was filed by Washington University in St. Louis. No other authors report any conflicts of interest.Clinical TrialNCT04727424Clinical Protocols https://gatesopenresearch.org/articles/5-117/v1 Funding StatementThe trial was supported by FastGrants and the Rainwater Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial complied with the International Conference of Harmonization: Good Clinical Practices, as well as local regulatory requirements and research ethics by local and national ethics boards in Brazil (CONEP CAAE: 41174620.0.1001.5120, approval letter 5.501.284) and the Hamilton Integrated Research Ethics Board (HiREB, approval letter 13390) in Canada.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTrial data are shared with the International COVID-19 Data Alliance (ICODA). ER -